

# CHBRP Analyses of California Assembly and Senate Bills

Status as of July 29, 2020

2019-2020 California State Legislature



CHBRP generally analyzes bills prior to their first Senate or Assembly Health Committee hearing. Analyses and analyzed bill language are available at [http://chbrp.org/completed\\_analyses/index.php](http://chbrp.org/completed_analyses/index.php). As bills move through both Legislative chambers, bills may be amended, which may alter expected impacts. The table, below, indicates the most current version of each analyzed bill and the extent to which CHBRP's analyses are still applicable. Current bill language and the bill status are available at <http://leginfo.legislature.ca.gov/>.

The requesting Committee (Senate or Assembly) alerted CHBRP that several bills analyzed by CHBRP in 2020, in part in consideration of the COVID-19 pandemic, were not being scheduled for a policy committee hearing (see indication under "version" in the table, below). CHBRP has posted all completed reports, as all may be of use to stakeholders considering future legislative action on the subject.

| Bill   | Version  | Notes   |
|--|--|---|
| AB 1904 (Boerner Horvath) Pelvic Floor Physical Therapy  | Introduced – 1/8/20<br><i>No initial health committee hearing scheduled</i>  | All portions of CHBRP's analysis remain relevant. |
| AB 1986 (Gipson) Colorectal Cancer Screening and Testing | Introduced – 1/23/20<br><i>No initial health committee hearing scheduled</i> | All portions of CHBRP's analysis remain relevant. |
| AB 2144 (Arambula) Step Therapy and Prior Authorization  | Amended – 3/12/20<br><i>No initial health committee hearing scheduled</i>    | All portions of CHBRP's analysis remain relevant. |
| AB 2203 (Nazarian) Insulin Cost-Sharing Cap              | Amended – 7/9/20   | All portions of CHBRP's analysis remain relevant. |
| AB 2204 (Arambula) Sexually Transmitted Diseases         | Amended – 2/27/20<br><i>No initial health committee hearing scheduled</i>    | All portions of CHBRP's analysis remain relevant. |

| Bill  | Version  | Notes  |
|---|--|--|
| AB 2242 (Levine) Mental Health Services                                   | Introduced – 2/13/20<br><i>No initial health committee hearing scheduled</i> | All portions of CHBRP's analysis remain relevant.  |
| AB 2258 (Reyes, Bonta, Limón, McCarty) Doula Care: Medi-Cal Pilot Program | Introduced – 2/13/20<br><i>No initial health committee hearing scheduled</i> | All portions of CHBRP's analysis remain relevant.  |
| AB 2625 (Boerner Horvath) Emergency Ground Medical Transportation         | Introduced – 2/20/20<br><i>No initial health committee hearing scheduled</i> | All portions of CHBRP's analysis remain relevant.  |
| AB 2640 (Gonzalez) Genetic Biomarker Testing                              | Introduced – 2/20/20<br><i>No initial health committee hearing scheduled</i> | Analysis is in progress.   |
| AB 2781 (Wicks) Treatment for Infertility                                 | Introduced – 2/20/20<br><i>No initial health committee hearing scheduled</i> | All portions of CHBRP's analysis remain relevant.  |
| SB 854 (Beall) Substance Use Disorders                                    | Amended – 4/24/20<br><i>No initial health committee hearing scheduled</i>    | The Medical Effectiveness and Policy Context sections remain fully relevant. Impacts projected for Benefit Coverage, Cost, Utilization and Public Health remain accurate in scale and direction.   |
| SB 855 (Wiener) Mental Health Parity                                      | Amended – 7/27/20  | Overall, all portions of CHBRP's analysis remain relevant. While specific discussions regarding aspects of bill language may only be partially relevant due to the amendments (medical necessity, utilization management, clinical guidelines, levels of care), the overall impacts remain relevant. |
| SB 888 (Wiener) Substance Use Disorder Services: Contingency Management   | Amended – 2/25/20<br><i>No initial health committee hearing scheduled</i>    | All portions of CHBRP's analysis remain relevant.  |

| Bill                                  | Version   | Notes   |
|---------------------------------------|---|---|
| SB 1452 (Morrell) Biological Products | Amended – 4/17/20<br><i>No initial health committee hearing scheduled</i> | CHBRP analyzed language as amended on 4/17/20 and therefore all portions of CHBRP’s analysis remain relevant. |